BCWM
NBIX icon

Bartlett & Co Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Bartlett & Co Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$334K Buy
+1,983
New +$294K ﹤0.01% 400
2021
Q3 		– Sell
-5
Closed -$487 – 1025
2021
Q2 		$487 Hold
5
– – ﹤0.01% 1027
2021
Q1 		$486 Hold
5
– – ﹤0.01% 1053
2020
Q4 		$479 Buy
+5
New +$483 ﹤0.01% 1155

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bartlett & Co Wealth Management's NBIX Position: Q2 2026 in Review

Bartlett & Co Wealth Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,983 shares worth $334K. The stake represents ﹤0.01% of the portfolio and ranks #400 among its holdings. This is a return to the name: Bartlett & Co Wealth Management previously reported a position in NBIX as recently as Q2 2021.

Bartlett & Co Wealth Management first reported a position in NBIX in Q4 2020 and has held it in 4 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bartlett & Co Wealth Management held 1,983 shares of Neurocrine Biosciences worth $334K as of Q2 2026.
  • Neurocrine Biosciences was a new Bartlett & Co Wealth Management position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Bartlett & Co Wealth Management's portfolio in Q2 2026, its #400 holding.
  • Bartlett & Co Wealth Management first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 4 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.